宾夕法尼亚州考虑限制人们获得昂贵的GLP-1重量损失药品,因为医疗补助费用飞涨。 Pennsylvania considers restricting access to costly GLP-1 weight-loss drugs due to soaring Medicaid costs.

GLP-1减重药品(如Wegovy和Ozempic)成本不断攀升, The rising cost of GLP-1 weight-loss drugs like Wegovy and Ozempic is putting pressure on state Medicaid programs. 宾夕法尼亚州医疗补助的覆盖率预计到2025年将耗资13亿美元, 导致决策者考虑限制获取这些药物, 可能要求病人首先尝试饮食和锻炼, Pennsylvania's Medicaid coverage is projected to cost $1.3 billion in 2025, leading policymakers to consider restricting access to these drugs, possibly requiring patients to try diet and exercise or less expensive medications first. 尽管费用高昂,但约有一半美国人支持医疗保险和医疗补助,以支付这些治疗肥胖症的药品,尽管医疗保险目前没有支付这些药品的费用。 Despite the high costs, about half of Americans support Medicare and Medicaid covering these drugs for obesity treatment, though Medicare does not currently cover them.